Is Jasper Therapeutics Inc. Common Stock a good investment? Jasper Therapeutics Inc. Common Stock (JSPR) is currently trading at 13.68 USD.
Earnings Schedule: Jasper Therapeutics Inc. Common Stock is expected to release its next earnings report on March 9, 2027. The market consensus estimate for Forward EPS is -21.15.
No, it does not currently pay a dividend.
Jasper Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be March 9, 2027. The company currently has a trailing EPS of -31.20.
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is headquartered in Redwood City, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 4, 2024 | 1:10 |
| Nov. 6, 2026 | 1:30 |
Community Discussion